Oculis Holding AG banner

Intrinsic Value

The intrinsic value of Oculis Holding AG (OCS) under the Base Case is 1.84 USD per share. Compared with the current market price of 8.35 USD, the stock appears Overvalued by 78% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

OCS Intrinsic Value
$1.84
Overvaluation 78%
Intrinsic Value
Price $8.35
O

OCS is valued in line with its history. A premium of this size has been typical over the past 5 years.

Monitor OCS
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value $1.47
Get notified when the price drops into your buy zone
Current Price $8.35
Intrinsic Value $1.84
Margin of Safety 20% $1.47
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to OCS

Fundamental Analysis

What Oculis Does

Pharmaceuticals Health Care

Oculis Holding AG is a biopharmaceutical company focused on eye and vision diseases. It develops medicines for conditions that damage the retina, the surface of the eye, and the optic nerve, aiming to deliver treatments that can be used more easily than traditional eye drugs. Its work is centered on clinical-stage drug development rather than running a broad commercial product business.

Headquarters
Switzerland CH
Employees
60
IPO date
Mar 3, 2023
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Oculis Holding AG

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one OCS stock?

The intrinsic value for Oculis Holding AG (OCS) under the Base Case is 1.84 USD.

Is OCS stock undervalued or overvalued?

Compared with the current market price of 8.35 USD, the stock appears Overvalued by 78% .

Back to Top